Fast Locator 2011-2012: Cangene bioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cangene bioPharma



CANGENE bioPharma, is a contract manufacturer, providing fill/finish and support services for over 30 years. Located in Baltimore, MD, USA, close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencies in the US, EU, and Japan.

CANGENE bioPharma’s fill/finish services include:

  • Vial filling (3cc-100cc) - batches up to 85,000 5cc vials
  • Lyophilization (2 x 240 sq ft lyophilizers)
  • Syringe filling – 0.5cc–20cc syringes
  • Terminal Sterilization – with steam

CANGENE bioPharma prides itself on providing outstanding and flexible support to its partner companies. From clinical through commercial launch, CANGENE bioPharma has the experience, knowledgeable personnel and involved management team to ensure our partners’ products proceed from project initiation through manufacturing quickly with an emphasis on exceptional quality.

CANGENE bioPharma provides services to a worldwide customer base, including large, small and virtual pharmaceutical and biotechnology companies. CANGENE bioPharma produces products that are distributed in over 50 countries by our clients.


Regions covered:

North America


Outsourcing services provided:

Development and Phase I/II CTM

  • Injectable products development

Commercial Manufacturing

  • Injectables

Analytical Services

  • Chemistry and stability
  • Microbiology

Website:

www.cangenebiopharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here